论文部分内容阅读
德国拜耳化学公司宣布,抗溶血症新药“KOGENATEBayer”已经得到了欧洲医药局所属的医药制品委员会的认可,批准其作为治疗血液病“A性溶血症(HaemophilieA)”的药品。“KOGENATEBayer”是一种第二代复合再生性凝血因子(Blutgerinnungsfaktor)。这种因子的最终产品中没有添加人体
Germany’s Bayer Chemie AG announced that KOGENATE Bayer, a new antihemolytic drug approved by the Medicinal Products Commission of the European Medicines Agency, has approved it as a drug for the treatment of haemophilia “HaemophilieA”. “KOGENATE Bayer” is a second generation of complex regenerative factor (Blutgerinnungsfaktor). No human body was added to the final product of this factor